GRAIL (GRAL) is back in focus after multiple law firms launched securities class action lawsuits tied to disclosures around its NHS Galleri trial, which did not achieve its primary endpoint on late stage cancer reduction.

The stock has been volatile, with a 39.71% 90 day share price return contrasting with a year to date share price decline of 32.31%. The 1 year total shareholder return of 43.51% points to momentum that has recently faded following the NHS Galleri headline and ensuing lawsuits.

If this mix of clinical results and legal risk has you rethinking concentration in a single healthcare stock, it may be worth scanning for other healthcare AI opportunities through the 40 healthcare AI stocks.

With GRAL up 39.7% over 90 days but still down 32.3% year to date, and trading around a 10% discount to the US$66 analyst target, are investors seeing mispriced clinical risk, or is the market already factoring in future growth?

Most Popular Narrative: 10% Undervalued

With GRAIL last closing at $60.16 against a narrative fair value of about $66.86, the current price sits below what this widely followed model implies. This puts the recent volatility in a different light for anyone focused on longer term assumptions.

Ongoing positive clinical trial results including substantially higher cancer detection and positive predictive value with consistent specificity for Galleri in population scale studies are setting the stage for robust FDA approval and broad payer reimbursement, which could unlock significant new revenue streams and accelerate top line growth.

Want to see what is baked into that gap between price and fair value? The narrative leans on rapid revenue expansion, margin repair, and a rich future earnings multiple that is more often associated with mature sector leaders, not a company that is still reporting steep losses. Curious which assumptions really carry the model and how tightly they are linked to trial readouts and reimbursement traction.

Result: Fair Value of $66.86 (UNDERVALUED)

However, the narrative still hinges on two fragile pillars: trial outcomes that support broad reimbursement and GRAIL’s ability to rein in sizable ongoing losses.

Next Steps

Seeing both legal risk and valuation support in the story, it makes sense to move quickly and test the assumptions against your own view using the 2 key rewards and 4 important warning signs.

Looking for more investment ideas?

If GRAIL has sharpened your thinking about risk and reward, broaden your watchlist now so you are not relying on a single story.

• Target steady compounding by reviewing companies with established payouts and resilient yields through the 8 dividend fortresses.
• Hunt for quality at a discount by scanning the 46 high quality undervalued stocks that pair solid fundamentals with prices below intrinsic estimates.
• Prioritise peace of mind by focusing on 67 resilient stocks with low risk scores that score well on balance sheet strength and business stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.